title: Update on the Use of Biologic Therapy in Ulcerative Colitis.
abstract: Ulcerative colitis (UC) is a major form of inflammatory bowel disease and is characterized by chronic inflammation of the colon and rectum and by alternating periods of flares and remissions. Symptoms may include rectal bleeding, abdominal pain, and diarrhea. The pathogenesis of UC is complex and involves a combination of immune dysregulation, genetics, environmental factors, and microbiota. The goal of medical treatment is to induce and maintain remission. Traditionally, the treatment options for UC included 5-aminosalicylates, corticosteroids, and immunomodulators. However, over the past decade, with the approval of various biologic agents for treatment of UC, the management of UC has been revolutionized. Currently, the FDA-approved biologics for treatment of UC include infliximab, adalimumab, golimumab, and vedolizumab. There are a number of other agents which are under investigation and may become available soon as treatment options for UC. The purpose of this article is to provide a summary of various biologics in the treatment of UC.
authors.affiliation: Department of Gastroenterology and Hepatology, University of Connecticut, Farmington, CT, USA.
authors.forename: Aakash
authors.initials: A
authors.lastname: Aggarwal
authors.affiliation: Department of Internal Medicine, University of Connecticut, Farmington, CT, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Sabol
authors.affiliation: Department of Gastroenterology and Hepatology, University of Connecticut, 263 Farmington Avenue, Farmington, CT, 06032, USA. hvaziri@uchc.edu.
authors.forename: Haleh
authors.initials: H
authors.lastname: Vaziri
keywords: Adalimumab; Biologics; Golimumab; Infliximab; Ulcerative colitis; Vedolizumab